Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P51160
UPID:
PDE6C_HUMAN
Alternative names:
cGMP phosphodiesterase 6C
Alternative UPACC:
P51160; A6NCR6; Q5VY29
Background:
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha', also known as cGMP phosphodiesterase 6C, plays a pivotal role in the visual system. It is crucial for light detection and cone phototransduction by modulating intracellular levels of cGMP, a key messenger in visual signal transduction.
Therapeutic significance:
Linked to Cone dystrophy 4 and Achromatopsia 5, this protein's dysfunction underscores its importance in retinal diseases. Understanding its role could pave the way for innovative treatments targeting these visual impairments.